Nuveen
LXEO icon

Nuveen’s Lexeo Therapeutics LXEO Stock Holding History

Nuveen’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$933K Buy
200,417
+17,442
+10% +$94.3K ﹤0.01% 2976
2026
Q1 		$1.05M Sell
182,975
-28,554
-13% -$202K ﹤0.01% 2568
2025
Q4 		$2.1M Buy
211,529
+178,427
+539% +$1.63M ﹤0.01% 2272
2025
Q3 		$220K Hold
33,102
– – ﹤0.01% 3135
2025
Q2 		$133K Sell
33,102
-2,948
-8% -$9.69K ﹤0.01% 3229
2025
Q1 		$125K Hold
36,050
– – ﹤0.01% 3195
2024
Q4 		$237K Hold
36,050
– – ﹤0.01% 3175
2024
Q3 		$326K Buy
36,050
+17,757
+97% +$212K ﹤0.01% 3127
2024
Q2 		$293K Buy
18,293
+4,815
+36% +$69.9K ﹤0.01% 3155
2024
Q1 		$211K Buy
+13,478
New +$211K ﹤0.01% 3171

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Nuveen's LXEO Position: Q2 2026 in Review

Nuveen increased its Lexeo Therapeutics (LXEO) stake by 9.5% in Q2 2026, buying an estimated $94.3K and bringing the position to 200,417 shares worth $933K. The position accounts for ﹤0.01% of the portfolio, ranked #2976.

Nuveen first reported a position in LXEO in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.1M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Nuveen held 200,417 shares of Lexeo Therapeutics worth $933K as of Q2 2026.
  • Nuveen bought 17,442 Lexeo Therapeutics shares in Q2 2026, an estimated $94.3K.
  • Lexeo Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2976 holding.
  • Nuveen first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Nuveen's Lexeo Therapeutics position peaked at $2.1M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.